BIM
SPHS

Baldwin Investment Management’s Sophiris Bio, Inc. SPHS Stock Holding History

Baldwin Investment Management’s Portfolio SPHS Stock Details SPHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-10,500
Closed -$35K – 139
2014
Q1 		$35K Hold
10,500
– – 0.02% 136
2013
Q4 		$39K Buy
+10,500
New +$44.4K 0.02% 135

Other funds holding SPHS

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Baldwin Investment Management's SPHS Position: Q2 2014 in Review

Baldwin Investment Management sold out of Sophiris Bio, Inc. (SPHS) in Q2 2014, closing a stake of 10,500 shares — an estimated $35K sold.

Baldwin Investment Management first reported a position in SPHS in Q4 2013 and held it in 2 quarters. The position peaked at $39K in Q4 2013. 18 funds tracked by Wall St. Rank hold SPHS as of Q2 2014.

  • Baldwin Investment Management reported no remaining Sophiris Bio, Inc. position as of Q2 2014 after selling out during the quarter.
  • Baldwin Investment Management sold 10,500 Sophiris Bio, Inc. shares in Q2 2014, an estimated $35K.
  • Baldwin Investment Management first reported a position in Sophiris Bio, Inc. in Q4 2013 and held it in 2 quarters.
  • Baldwin Investment Management's Sophiris Bio, Inc. position peaked at $39K in Q4 2013.
  • 18 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q2 2014.

Based on Baldwin Investment Management's 13F filing for Q2 2014, filed 8 Aug 2014.